Bevacizumab in non small cell lung cancer: development, current status and issues.

Sandomenico, C; Costanzo, R; Carillio, G; Piccirillo, M C; Montanino, A; Di Maio, M; Rocco, G; Normanno, N; Perrone, F; Morabito, A

Sandomenico, C; Costanzo, R; Carillio, G; Piccirillo, M C; Montanino, A; Di Maio, M; Rocco, G; Normanno, N; Perrone, F; Morabito, A.

Affiliation

Sandomenico C; Thoraco-Pulmonary Department, National Cancer Institute, Naples, Italy.

Curr Med Chem ; 19(7): 961-71, 2012.

Article in En | MEDLINE | ID: mdl-22214464

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal, Humanized/adverse effects; Bevacizumab; Clinical Trials as Topic; Disease-Free Survival; Hemorrhage; Humans

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Curr Med Chem Journal subject: QUIMICA Year: 2012 Document type: Article Affiliation country: Italy Country of publication: United Arab Emirates

Search on Google

Add to My VHL

XML

PubMed Links